Literature DB >> 17880359

Age-related changes in the structure and function of skeletal muscles.

John A Faulkner1, Lisa M Larkin, Dennis R Claflin, Susan V Brooks.   

Abstract

1. For animals of all ages, during activation of skeletal muscles and the subsequent contraction, the balance between the force developed by the muscle and the external load determines whether the muscle shortens, remains at fixed length (isometric) or is lengthened. With maximum activation, the force developed is least during shortening, intermediate when muscle length is fixed and greatest during lengthening contractions. During lengthening contractions, when force is high, muscles may be injured by the contractions. 2. 'Frailty' and 'failure to thrive' are most frequently observed in elderly, physically inactive people. A 'frail' person is defined as one of small stature, with muscles that are atrophied, weak and easily fatigued. The condition of 'failure to thrive' is typified by a lack of response to well-designed programmes of nutrition and physical activity. 3. With ageing, skeletal muscle atrophy in humans appears to be inevitable. A gradual loss of muscle fibres begins at approximately 50 years of age and continues such that by 80 years of age, approximately 50% of the fibres are lost from the limb muscles that have been studied. For both humans and rats, the observation that the timing and magnitude of the loss of motor units is similar to that for muscle fibres suggests that the mechanism responsible for the loss of fibres and the loss of whole motor units is the same. The degree of atrophy of the fibres that remain is largely dependent on the habitual level of physical activity of the individual. 4. 'Master athletes' maintain a high level of fitness throughout their lifespan. Even among master athletes, performance of marathon runners and weight lifters declines after approximately 40 years of age, with peak levels of performance decreased by approximately 50% by 80 years of age. The success of the master athletes and of previously sedentary elderly who undertake well-designed, carefully administered training programmes provide dramatic evidence that age-associated atrophy, weakness and fatigability can be slowed, but not halted.

Entities:  

Mesh:

Year:  2007        PMID: 17880359     DOI: 10.1111/j.1440-1681.2007.04752.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  176 in total

Review 1.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

Review 2.  Innervation and neuromuscular control in ageing skeletal muscle.

Authors:  Russell T Hepple; Charles L Rice
Journal:  J Physiol       Date:  2015-12-21       Impact factor: 5.182

Review 3.  Successful aging: Advancing the science of physical independence in older adults.

Authors:  Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor
Journal:  Ageing Res Rev       Date:  2015-10-14       Impact factor: 10.895

4.  Genome-wide Associations Reveal Human-Mouse Genetic Convergence and Modifiers of Myogenesis, CPNE1 and STC2.

Authors:  Ana I Hernandez Cordero; Natalia M Gonzales; Clarissa C Parker; Greta Sokolof; David J Vandenbergh; Riyan Cheng; Mark Abney; Andrew Sko; Alex Douglas; Abraham A Palmer; Jennifer S Gregory; Arimantas Lionikas
Journal:  Am J Hum Genet       Date:  2019-11-21       Impact factor: 11.025

5.  Neurophysiological correlates of aging-related muscle weakness.

Authors:  Ela B Plow; David A Cunningham; Corin Bonnett; Dina Gohar; Mehmed Bayram; Alexandria Wyant; Nicole Varnerin; Bernadett Mamone; Vlodek Siemionow; Juliet Hou; Andre Machado; Guang H Yue
Journal:  J Neurophysiol       Date:  2013-09-11       Impact factor: 2.714

Review 6.  Quality of life in sarcopenia and frailty.

Authors:  René Rizzoli; Jean-Yves Reginster; Jean-François Arnal; Ivan Bautmans; Charlotte Beaudart; Heike Bischoff-Ferrari; Emmanuel Biver; Steven Boonen; Maria-Luisa Brandi; Arkadi Chines; Cyrus Cooper; Sol Epstein; Roger A Fielding; Bret Goodpaster; John A Kanis; Jean-Marc Kaufman; Andrea Laslop; Vincenzo Malafarina; Leocadio Rodriguez Mañas; Bruce H Mitlak; Richard O Oreffo; Jean Petermans; Kieran Reid; Yves Rolland; Avan Aihie Sayer; Yannis Tsouderos; Marjolein Visser; Olivier Bruyère
Journal:  Calcif Tissue Int       Date:  2013-07-05       Impact factor: 4.333

7.  Architectural analysis and predicted functional capability of the human latissimus dorsi muscle.

Authors:  Michael E Gerling; Stephen H M Brown
Journal:  J Anat       Date:  2013-06-13       Impact factor: 2.610

8.  Maximal and explosive strength training elicit distinct neuromuscular adaptations, specific to the training stimulus.

Authors:  Neale A Tillin; Jonathan P Folland
Journal:  Eur J Appl Physiol       Date:  2013-12-01       Impact factor: 3.078

Review 9.  Influence of body weight on bone mass, architecture and turnover.

Authors:  Urszula T Iwaniec; Russell T Turner
Journal:  J Endocrinol       Date:  2016-06-27       Impact factor: 4.286

10.  Longitudinal analysis of early stage sarcopenia in aging rhesus monkeys.

Authors:  Susan H McKiernan; Ricki Colman; Marisol Lopez; T Mark Beasley; Richard Weindruch; Judd M Aiken
Journal:  Exp Gerontol       Date:  2008-10-17       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.